Biomea Fusion Q2 Loss Narrows to $8.3M, Cash Runway Extended to Q2 2027
BMEA sits 41% above its 52-week low of $0.872.
Summary
Biomea Fusion reported a Q2 net loss of $8.3 million, down from $12.4 million in Q1, driven by continued cost reductions in R&D and G&A. The company extended its cash runway projection into Q2 2027, a quarter beyond the prior estimate. Initial obesity trial data for icovamenib is expected in Q3 2026, with diabetes trial data to follow in early 2027. The results show progress in managing burn rate while advancing clinical programs, though the company remains pre-revenue with a modest market cap.
At the time of this announcement, BMEA was trading at $1.23 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $91.1M. The 52-week trading range was $0.87 to $2.99. This news item was assessed with positive market sentiment and an importance score of 7 out of 10. Source: Reuters.